Continuous treatment with lenalidomide/dexamethasone significantly improved survival in patients with transplant-ineligible newly diagnosed multiple myeloma.
Experience with the recently enacted California End of Life Option Act has shown that a high percentage of patients who requested aid-in-dying drugs in California have proceeded with ingesting the drugs. The majority of these requests were made by terminal cancer patients.
The FDA has expanded the label for cabozantinib (Cabometyx) to include first-line treatment of advanced renal cell carcinoma regardless of treatment status. Cabozantinib was initially approved in patients who had previously received anti-angiogenic therapy.
The FDA has approved nivolumab for the adjuvant treatment of melanoma; it showed superiority compared with the standard of care in this patient population.
Early disease progression for chronic lymphocytic leukemia was a robust prognostic factor for worse overall survival in patients treated with chemoimmunotherapy.
Use of a brief educational video increased hairdressers’ knowledge of melanoma detection and improved their self-confidence to detect skin lesions.
Venetoclax has durable clinical activity in patients with relapsed/refractory chronic lymphocytic leukemia whose disease progressed during or after ibrutinib therapy.
The addition of tumor-treating fields to maintenance temozolomide chemotherapy significantly delayed progression and improved overall survival in patients with glioblastoma who had received standard radiochemotherapy compared with maintenance temozolomide alone.
A new study has found that there are significant gaps in participation among people aged 75 and older in clinical trials of hematologic malignancies when considered against the incidence of these malignancies in this age group.
CAR T cells targeting CD19 can be effective at treating relapsed/refractory diffuse large B-cell lymphoma or follicular lymphoma, with high rates of durable remission.